A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.
anthracyclines
cyclophosphamide
fosaprepitant
injection site reaction
nausea
neurokinin 1 receptor antagonists
vomiting
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 04 2022
15 04 2022
Historique:
revised:
10
12
2021
received:
21
10
2021
accepted:
13
12
2021
pubmed:
20
1
2022
medline:
7
4
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Fosnetupitant (FosNTP), an intravenous neurokinin 1 receptor antagonist, demonstrated a favorable safety profile with a potentially low risk of injection site reactions (ISRs) and promising antiemetic efficacy in patients receiving cisplatin-based highly emetogenic chemotherapy in a previous phase 2 study. We conducted a randomized, double-blind safety study to evaluate the safety profile of FosNTP, including ISRs, in patients receiving doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide (AC/EC) chemotherapy. Patients scheduled to receive AC/EC were randomized 1:1 to receive 235 mg of FosNTP or 150 mg of fosaprepitant (FosAPR), both in combination with 0.75 mg of intravenous palonosetron and 9.9 mg of dexamethasone on day 1. The stratification factors were age category (<55 vs ≥55 years) and study site. The primary end point was the incidence of treatment-related adverse events (TRAEs) with FosNTP. Overall, 102 patients were randomized to FosNTP (n = 52) or FosAPR (n = 50), and all were treated with the study drug and evaluated for safety. The primary end point, the incidence of TRAEs, was similar with FosNTP (21.2%; 95% confidence interval [CI], 11.1%-34.7%) and FosAPR (22.0%; 95% CI, 11.5%-36.0%), with any-cause ISRs observed in 5.8% and 26.0% of patients, respectively, and treatment-related ISRs observed in 0% and 10.0%, respectively. The overall (0-120 hour) complete response (defined as no emetic event and no rescue medication) rate, standardized by age category in the full analysis set, was 45.9% (23 of 51 patients) with FosNTP and 51.3% (25 of 49 patients) with FosAPR. FosNTP demonstrated a favorable safety profile with a very low risk of ISRs in the AC/EC setting.
Sections du résumé
BACKGROUND
Fosnetupitant (FosNTP), an intravenous neurokinin 1 receptor antagonist, demonstrated a favorable safety profile with a potentially low risk of injection site reactions (ISRs) and promising antiemetic efficacy in patients receiving cisplatin-based highly emetogenic chemotherapy in a previous phase 2 study. We conducted a randomized, double-blind safety study to evaluate the safety profile of FosNTP, including ISRs, in patients receiving doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide (AC/EC) chemotherapy.
METHODS
Patients scheduled to receive AC/EC were randomized 1:1 to receive 235 mg of FosNTP or 150 mg of fosaprepitant (FosAPR), both in combination with 0.75 mg of intravenous palonosetron and 9.9 mg of dexamethasone on day 1. The stratification factors were age category (<55 vs ≥55 years) and study site. The primary end point was the incidence of treatment-related adverse events (TRAEs) with FosNTP.
RESULTS
Overall, 102 patients were randomized to FosNTP (n = 52) or FosAPR (n = 50), and all were treated with the study drug and evaluated for safety. The primary end point, the incidence of TRAEs, was similar with FosNTP (21.2%; 95% confidence interval [CI], 11.1%-34.7%) and FosAPR (22.0%; 95% CI, 11.5%-36.0%), with any-cause ISRs observed in 5.8% and 26.0% of patients, respectively, and treatment-related ISRs observed in 0% and 10.0%, respectively. The overall (0-120 hour) complete response (defined as no emetic event and no rescue medication) rate, standardized by age category in the full analysis set, was 45.9% (23 of 51 patients) with FosNTP and 51.3% (25 of 49 patients) with FosAPR.
CONCLUSIONS
FosNTP demonstrated a favorable safety profile with a very low risk of ISRs in the AC/EC setting.
Identifiants
pubmed: 35045185
doi: 10.1002/cncr.34088
pmc: PMC9306508
doi:
Substances chimiques
Anthracyclines
0
Antiemetics
0
Dexamethasone
7S5I7G3JQL
Cyclophosphamide
8N3DW7272P
Banques de données
JapicCTI
['JapicCTI-194691']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1692-1698Subventions
Organisme : Taiho Pharmaceutical
Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Oncologist. 2020 Mar;25(3):e589-e597
pubmed: 32162813
Support Care Cancer. 2014 May;22(5):1313-7
pubmed: 24402411
J Clin Oncol. 2017 Oct 1;35(28):3240-3261
pubmed: 28759346
J Cancer. 2014 Apr 24;5(5):390-7
pubmed: 24799957
Cancer. 2022 Apr 15;128(8):1692-1698
pubmed: 35045185
Support Care Cancer. 2015 Jan;23(1):55-9
pubmed: 24964876
Support Care Cancer. 2014 Jun;22(6):1461-6
pubmed: 24402412
Ann Oncol. 2016 Sep;27(suppl 5):v119-v133
pubmed: 27664248
Int J Clin Oncol. 2021 Jan;26(1):1-17
pubmed: 33161452
Cancer Manag Res. 2016 Jun 22;8:77-82
pubmed: 27382332
Anticancer Res. 2015 Jan;35(1):379-83
pubmed: 25550575
Cancer. 2019 Nov 15;125(22):4076-4083
pubmed: 31381152
Ann Oncol. 2013 Apr;24(4):1067-73
pubmed: 23117073
Cancer Med. 2020 May;9(10):3319-3327
pubmed: 32168551
Mol Clin Oncol. 2016 Apr;4(4):603-606
pubmed: 27073673
Cancer Chemother Pharmacol. 2013 Sep;72(3):509-13
pubmed: 23860958